Targeting OSMR in glioma stem cells.
Department of Oncology, Integrated Program in Neuroscience, McGill University, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
Sushmetha
S
Mohan
Department of Neuroscience, Washington University School of Medicine, St. Louis, MO, USA.
Azad
A
Bonni
Department of Oncology, Integrated Program in Neuroscience, McGill University, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
Arezu
A
Jahani-Asl
D000818:Animals; D001932:Brain Neoplasms / Q000378:metabolism*; D049109:Cell Proliferation; D015195:Drug Design; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D020869:Gene Expression Profiling; D005909:Glioblastoma / Q000378:metabolism*; D005910:Glioma / Q000378:metabolism*; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D014411:Neoplastic Stem Cells / Q000166:cytology*; D053681:Oncostatin M Receptor beta Subunit / Q000378:metabolism*; D010766:Phosphorylation; D015398:Signal Transduction; D016896:Treatment Outcome
C508348:OSMR protein, human; D053681:Oncostatin M Receptor beta Subunit; D066246:ErbB Receptors
EGFRvIII; Neuroscience; OSMR; STAT3; glioblastoma; tumor stem cells